Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olanzapine-induced mania.

Journal of osteopathic medicine·2024
Same author

Disparities and Medical Expenditure Implications in Pediatric Tele-Mental Health Services During the COVID-19 Pandemic in Mississippi.

The journal of behavioral health services & research·2024
Same author

Tele-Mental Health Service: Unveiling the Disparity and Impact on Healthcare Access and Expenditures during the COVID-19 Pandemic in Mississippi.

International journal of environmental research and public health·2024
Same author

Significant cognitive impairment likely associated with COVID-19 infection with relatively nonsevere symptoms.

Journal of osteopathic medicine·2022
Same author

Motivating and Discouraging Factors for Bipolar Patient Participation in Genomic Research.

Public health genomics·2021
Same author

Complicated Withdrawal Phenomena During Benzodiazepine Cessation in Older Adults.

The Journal of the American Osteopathic Association·2019
Same journal

Potential Mechanisms of Trimetazidine and Coenzyme Q10 Against Antipsychotic-Induced Myocarditis: A Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation Study.

CNS neuroscience & therapeutics·2026
Same journal

Sympathetic Overactivation Drives Neurogenic Alveolar Epithelial Pyroptosis via the PIEZO2-ER Stress Pathway in Acute Lung Injury Following Intracerebral Hemorrhage.

CNS neuroscience & therapeutics·2026
Same journal

Roles of Microglia in Cerebral Small Vessel Disease.

CNS neuroscience & therapeutics·2026
Same journal

Mapping the Disrupted Connectome in Spinocerebellar Ataxia Type 3: A Network-Based Statistics Study Identifying Novel Therapeutic Targets for Neuromodulation.

CNS neuroscience & therapeutics·2026
Same journal

EEG Functional Connectivity Associated With Antidepressant Response to Transcutaneous Electrical Cranial-Auricular Acupoint Stimulation.

CNS neuroscience & therapeutics·2026
Same journal

Cingulate Gradient Dysfunction in End-Stage Renal Disease: Associations With Clinical Phenotypes and Exploratory Transcriptomic Signatures.

CNS neuroscience & therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Antidepressant-induced suicidality: an update.

Roy R Reeves1, Mark E Ladner

  • 1G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS 39216, USA. roy.reeves@va.gov

CNS Neuroscience & Therapeutics
|June 18, 2010
PubMed
Summary
This summary is machine-generated.

Antidepressant medications may increase the risk of suicidal thoughts and behaviors in young patients. Healthcare providers should carefully monitor patients starting new antidepressants due to this potential risk.

Related Experiment Videos

Last Updated: Jun 12, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Area of Science:

  • Psychiatry
  • Clinical Pharmacology

Background:

  • Antidepressant use in pediatric and adolescent populations is associated with potential worsening depression and increased suicidality.
  • The United States Food and Drug Administration mandates a black box warning for antidepressants concerning this risk in individuals up to age 24.

Purpose of the Study:

  • To provide an updated review of the ongoing controversy regarding antidepressants as a potential cause of suicidal ideation or behavior.
  • To highlight the importance of monitoring patients during antidepressant treatment.

Main Methods:

  • Review of existing literature and studies on antidepressant-induced suicidality in pediatric, adolescent, and adult populations.
  • Analysis of the evidence supporting and refuting the link between antidepressants and suicidal behavior.

Main Results:

  • Antidepressant-induced suicidality is an uncommon but recognized phenomenon.
  • Studies on adult populations have yielded conflicting results regarding increased suicidality risk.

Conclusions:

  • Close monitoring and diligent follow-up care are essential for patients initiating new antidepressant therapies.
  • The potential for antidepressant-induced suicidality necessitates careful consideration in clinical practice.